초록 ▼

There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specif

There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specific cell-surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. IGFBP-3 and P4.33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4.33 is an important mediator of IGF-independent growth inhibitory actions of IGFBP-3. The P4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression.

대표청구항 ▼

We claim: 1. A method for treating cancer in a mammal, comprising: directly injecting a recombinant vector comprising a polynucleotide encoding a functional insulin-like growth factor binding protein-3 receptor (IGFBP-3R) into a tumor of a mammal such that the IGFBP-3R is expressed and tumor growth

We claim: 1. A method for treating cancer in a mammal, comprising: directly injecting a recombinant vector comprising a polynucleotide encoding a functional insulin-like growth factor binding protein-3 receptor (IGFBP-3R) into a tumor of a mammal such that the IGFBP-3R is expressed and tumor growth is inhibited, wherein the tumor is selected from the group consisting of breast, cervical, lung, non-small cell lung, colon and prostate tumors. 2. The method of claim 1, wherein the expression induces cellular apoptosis. 3. The method of claim 2, wherein the recombinant vector is an adeno or an adeno-associated virus (rAAV) vector. 4. The method of claim 2, wherein the cancer cells are prostate cancer cells. 5. The method of claim 2, wherein the recombinant vector is an adeno-associated virus (rAAV) vector, and wherein the cells are that of a prostate cancer. 6. The method of claim 2, further comprising administration of IGFBP-3, wherein said administering comprises direct introduction or injection of a recombinant IGFBP-3 expression vector into tumor tissue to afford vector-mediated expression of a therapeutically effective amount of IGFBP-3 in one or more cells of the tumor. 7. The method of claim 6, wherein the recombinant vector is an adeno-associated virus (rAAV) vector. 8. The method of claim 1, wherein the cancer is prostate cancer. 9. The method of claim 1, wherein the recombinant vector is a recombinant adeno or recombinant adeno-associated virus (rAAV) vector. 10. The method of claim 1, wherein the recombinant virus is a recombinant adeno-associated virus (rAAV) vector, and wherein said vector is administered by direct injection into a prostate tumor. 11. The method of claim 1, further comprising administration of IGFBP-3, wherein said administering comprises direct introduction or injection of a recombinant IGFBP-3 expression vector into tumor tissue to afford vector-mediated expression of a therapeutically effective amount of IGFBP-3 in one or more cells of the tumor. 12. The method of claim 11, wherein the recombinant IGFBP-3 expression vector is an adeno-associated virus (rAAV) vector, and wherein the cell is that of a prostate cancer.